Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Asthma Data Supports Advancing Program to Efficacy Trials
Dynavax Asthma Data Supports Advancing Program to Efficacy Trials Safety Confirmed; Biological Activity Indicates Reprogramming Of Immune System BERKELEY, Calif., July 28 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery,
View HTML
Toggle Summary Dynavax Completes Phase I Immunization in Pediatric Ragweed Allergy Trial
Dynavax Completes Phase I Immunization in Pediatric Ragweed Allergy Trial BERKELEY, Calif., Jun 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative
View HTML
Toggle Summary Dynavax Announces Initiation of Phase II/III Hepatitis B Trial
Dynavax Announces Initiation of Phase II/III Hepatitis B Trial BERKELEY, Calif., June 22 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent
View HTML
Toggle Summary Dynavax to Webcast Annual Meeting
Dynavax to Webcast Annual Meeting BERKELEY, Calif., June 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases
View HTML
Toggle Summary Dynavax Announces CFO to Step Down
Dynavax Announces CFO to Step Down BERKELEY, Calif., May 20 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases
View HTML
Toggle Summary Dynavax Announces Full Enrollment of Phase II/III AIC Trial
Dynavax Announces Full Enrollment of Phase II/III AIC Trial BERKELEY, Calif., May 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent
View HTML
Toggle Summary Dynavax Reports 2004 First Quarter Results
Dynavax Reports 2004 First Quarter Results BERKELEY, Calif., May 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious
View HTML
Toggle Summary Dynavax Reports 2003 Fourth Quarter and Full Year Results
Dynavax Reports 2003 Fourth Quarter and Full Year Results BERKELEY, Calif., March 29 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent
View HTML
Toggle Summary /C O R R E C T I O N -- Dynavax Technologies Corporation/
/C O R R E C T I O N -- Dynavax Technologies Corporation/ In the news release, Dynavax Reports 2003 Fourth Quarter and Full Year Results, issued earlier today by Dynavax Technologies Corporation (Nasdaq: DVAX) over PR Newswire, the "Additional paid-in capital" line in the "Condensed Consolidated
View HTML
Toggle Summary Dynavax Full Year and Fourth Quarter Earnings Conference Call
Dynavax Full Year and Fourth Quarter Earnings Conference Call BERKELEY, Calif., March 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent
View HTML